Safety and Efficacy of Dalbavancin in Real Life: Retrospective Analysis of a Large Monocentric Case Series of Patients Treated for Skin/Soft Tissue and Other Difficult-to-Treat Infections

• Main Authors: Giustino Parruti (Author), Ennio Polilli (Author), Simona Coladonato (Author), Giorgia Rapacchiale (Author), Francesca Trave (Author), Elena Mazzotta (Author), Martina Bondanese (Author), Francesco Di Masi (Author), Davide Recinelli (Author), Serena Corridoni (Author), Alberto Costantini (Author), Stefano Ianniruberto (Author), Pierluigi Cacciatore (Author), Fabrizio Carinci (Author)
• Format: Book
• Published: MDPI AG, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

<b>Background:</b> Dalbavancin is a long-acting lipoglycopeptide, approved for treatment of skin and skin structure infections. Its PK/PD profile and safety allow for short hospital stays even in the case of difficult-to-treat infections requiring long courses of therapy, e.g., osteomyel...